Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Subcutaneous Avonex in Relapsing MS
NCT00784836Phase 3Terminated
- Sponsor
- Biogen
- Start
- Oct 2008
- Primary completion
- Feb 2009
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of interferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Neutralizing Antibodies to Interferon-beta at 18 months. Started Oct 2008; status: terminated.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00784836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784836.